Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation.

Attal, M; Canal, P; Schlaifer, D; Chatelut, E; Dezeuze, A; Huguet, F; Payen, C; Pris, J; Laurent, G

Attal, M; Canal, P; Schlaifer, D; Chatelut, E; Dezeuze, A; Huguet, F; Payen, C; Pris, J; Laurent, G.

Affiliation

Attal M; Department of Hematology, Purpan Hospital, Toulouse, France.

J Clin Oncol ; 12(1): 141-8, 1994 Jan.

Article in En | MEDLINE | ID: mdl-8270970

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Bone Marrow Diseases/prevention & control; Bone Marrow Transplantation; Lymphoma/drug therapy; Mitoxantrone/administration & dosage; Adult; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics; Bone Marrow Diseases/chemically induced; Carmustine/administration & dosage; Cyclophosphamide/administration & dosage; Etoposide/administration & dosage; Female; Humans; Male; Middle Aged; Mitoxantrone/adverse effects; Mitoxantrone/pharmacokinetics

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Bone Marrow Diseases / Antineoplastic Combined Chemotherapy Protocols / Bone Marrow Transplantation / Mitoxantrone / Lymphoma Type of study: Prognostic_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: J Clin Oncol Year: 1994 Type: Article Affiliation country: France

Search on Google

XML

PubMed Links